Zhejiang Medicine Co Ltd (SHG:600216) — Market Cap & Net Worth
Market Cap & Net Worth: Zhejiang Medicine Co Ltd (600216)
Zhejiang Medicine Co Ltd (SHG:600216) has a market capitalization of $1.79 Billion (CN¥12.23 Billion) as of September 24, 2026. Listed on the SHG stock exchange, this China-based company holds position #6632 globally and #1356 in its home market, demonstrating a 1.35% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Zhejiang Medicine Co Ltd's stock price CN¥12.72 by its total outstanding shares 961637750 (961.64 Million). Also see 600216 asset base for a full breakdown of the balance sheet.
Zhejiang Medicine Co Ltd Market Cap History: 2015 to 2026
Zhejiang Medicine Co Ltd's market capitalization history from 2015 to 2026. Data shows growth from $1.50 Billion to $1.79 Billion (3.12% CAGR). Also see Zhejiang Medicine Co Ltd (600216) cash conversion ratio for how efficiently the company converts equity into cash flow.
Index Memberships
Zhejiang Medicine Co Ltd is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Shanghai Shenzhen CSI 300
CSI300
|
$3.98 Trillion | 0.04% | #218 of 285 |
Weight: Zhejiang Medicine Co Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Zhejiang Medicine Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Zhejiang Medicine Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Zhejiang Medicine Co Ltd (600216) share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.22x
Zhejiang Medicine Co Ltd's market cap is 0.22 times its annual revenue
Latest Price to Earnings (P/E) Ratio
2.23x
Zhejiang Medicine Co Ltd's market cap is 2.23 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.55 Billion | $5.28 Billion | $450.10 Million | 0.29x | 3.44x |
| 2017 | $1.67 Billion | $5.69 Billion | $253.15 Million | 0.29x | 6.58x |
| 2018 | $1.08 Billion | $6.86 Billion | $364.55 Million | 0.16x | 2.97x |
| 2019 | $1.69 Billion | $7.04 Billion | $342.77 Million | 0.24x | 4.93x |
| 2020 | $1.82 Billion | $7.33 Billion | $717.40 Million | 0.25x | 2.53x |
| 2021 | $2.31 Billion | $9.13 Billion | $1.05 Billion | 0.25x | 2.21x |
| 2022 | $1.62 Billion | $8.12 Billion | $539.57 Million | 0.20x | 3.00x |
| 2023 | $1.51 Billion | $7.79 Billion | $429.64 Million | 0.19x | 3.51x |
| 2024 | $2.23 Billion | $9.38 Billion | $1.16 Billion | 0.24x | 1.92x |
| 2025 | $1.95 Billion | $8.88 Billion | $873.38 Million | 0.22x | 2.23x |
Competitor Companies of 600216 by Market Capitalization
Companies near Zhejiang Medicine Co Ltd in the global market cap rankings as of September 24, 2026. Review how tangible is Zhejiang Medicine Co Ltd's equity to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Zhejiang Medicine Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #524 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #586 globally with a market cap of $46.44 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #638 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #651 globally with a market cap of $42.68 Billion USD ( CN¥291.65 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #524 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #586 | GALDERMA GROUP AG | NYSE:GALDY | $46.44 Billion | $39.83 |
| #638 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.50 |
| #651 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $42.68 Billion | CN¥45.72 |
Zhejiang Medicine Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Zhejiang Medicine Co Ltd's market cap moved from $1.50 Billion to $ 1.79 Billion, with a yearly change of 3.12%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.79 Billion | -8.23% |
| 2025 | CN¥1.95 Billion | -12.61% |
| 2024 | CN¥2.23 Billion | +47.81% |
| 2023 | CN¥1.51 Billion | -6.79% |
| 2022 | CN¥1.62 Billion | -29.96% |
| 2021 | CN¥2.31 Billion | +27.37% |
| 2020 | CN¥1.82 Billion | +7.46% |
| 2019 | CN¥1.69 Billion | +56.04% |
| 2018 | CN¥1.08 Billion | -35.01% |
| 2017 | CN¥1.67 Billion | +7.63% |
| 2016 | CN¥1.55 Billion | +2.87% |
| 2015 | CN¥1.50 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 23rd, 2026 the market cap of Zhejiang Medicine Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.79 Billion USD |
| MoneyControl | $1.79 Billion USD |
| MarketWatch | $1.79 Billion USD |
| marketcap.company | $1.79 Billion USD |
| Reuters | $1.79 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Zhejiang Medicine Co Ltd
Zhejiang Medicine Co., Ltd. manufactures and sells life nutrition and pharmaceuticals products in China and internationally. The company offers synthetic vitamin E, vitamin A, natural vitamin E, ß-carotene, canthaxanthin, vancomycin hydrochloride, teicoplanin, and daptomycin. It also provides fat-soluble vitamins, quinolone antibiotics, anti-drug-resistant antibiotics, and other products, as well… Read more